



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

13.08.2025

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome of Board Meeting dated August 13, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday, 13th August, 2025**, at the office of company, have inter-alia approved the following businesses:

1. Financial Results:

a) Unaudited Standalone and Consolidated financial results of the Company for the quarter ended 30th June, 2025.

b) A N S K & Associates, Statutory Auditors of the Company, have issued the Limited Review Report of the Financial Results with unmodified opinion on the above-mentioned results.

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2025, along with the Limited Review Report issued by the Statutory Auditors.

2. Appointment of Mr. Debendra Kumar Sabat (DIN-00802225) as an Additional Independent Director of the Company.

Based on the recommendation of the Nomination and Remuneration Committee, Mr. Debendra Kumar Sabat (DIN-00802225) has been appointed as an Additional Independent Director of the Company with effect from 13th August, 2025 upto the forthcoming Annual General Meeting.

3. Re-appointment of Mr. Naresh Kumar Singla (DIN 00027448) as Managing Director

Based on the recommendation of the Nomination and Remuneration Committee, Mr. Naresh Kumar Singla (DIN 00027448) has been reappointed as the Managing Director of the Company

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

with effect from 1st April, 2026 to 31st March, 2031, subject to the approval of the Shareholders of the Company.

4. Re-appointment of Mr. Suresh Chand Singla (DIN 00027706) as Managing Director

Based on the recommendation of the Nomination and Remuneration Committee, Mr. Suresh Chand Singla (DIN 00027706) has been re-appointed as the Managing Director of the Company with effect from 1st April, 2026 to 31st March, 2031, subject to the approval of the Shareholders of the Company.

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015") read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, concerning the above appointment/ re-appointment w.r.t point No 2, 3 and 4 as mentioned above is enclosed as **Annexure I** to this intimation.

5. Annual General Meeting

Please be informed that the **Thirty-Third (33rd) Annual General Meeting ("AGM")** of the Company has been scheduled for Friday, September 26, 2025, through Video Conferencing ("VC")/Other AudioVisual Means ("OAVM").

Annual Report and Notice of the AGM shall be sent in due course. The same shall also be uploaded on the Company's website.

6. Cut-off Date

The Company has fixed Friday, September 19, 2025 as the "Cut-off Date" for the purpose of determining the members eligible to vote on the resolutions set out in the Notice of the AGM.

7. Record Date

As informed by the Company on May 30, 2025, Board of Directors has recommended a final dividend of Rs. 2.00/- (Rupees Two Only) per shares. The record date for the purpose of the Annual General Meeting and payment of dividend is Friday, **19th September, 2025**.

8. Book Closure date

The Company has fixed Book Closure date from 21st September, 2025 to 26th September, 2025 (both days inclusive).



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 04:10 P.M.

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com .

The current list of Directors with effect from 13th August, 2025 is enclosed as “Annexure-II”

Request to kindly take this information on record and acknowledge.

**For and on behalf of
Titan Biotech Limited**

Charanjit Singh
Company Secretary & Compliance Officer
M.No A12726
Encl: As above



Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended June 30, 2025, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**AKHIL
MITTAL**

Digitally signed
by AKHIL MITTAL
Date: 2025.08.13
12:49:23 +05'30'



4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

AKHIL

MITTAL

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 13.08.2025

Place: New Delhi

UDIN: 25517856BMKXJH8266

Digitally signed by
AKHIL MITTAL
Date: 2025.08.13
12:49:47 +05'30'



Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended June 30, 2025, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**AKHIL
MITTAL**

Digitally signed by
AKHIL MITTAL
Date: 2025.08.13
12:47:22 +05'30'



4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited and Titan Media Limited
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs.70.20 lacs and total comprehensive income of Rs.70.20 Lacs for the Quarter ended 30th June 2025, as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of M/s Peptech biosciences Limited and M/s Titan Media Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.
Our conclusion is not modified in respect of this matter.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

AKHIL

MITTAL

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 13.08.2025

Place: New Delhi

UDIN: 25517856BMKXJI4672

Digitally signed by
AKHIL MITTAL
Date: 2025.08.13
12:47:56 +05'30'

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2025

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	4,649.64	3,516.93	4,311.46	15,645.08
	Other Income	72.22	138.07	62.37	391.25
	Total Income	4,721.86	3,655.00	4,373.83	16,036.33
2	EXPENSES				
	Cost of Materials Consumed	1,855.28	1,730.44	2,234.58	7,548.08
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	539.67	(229.18)	(57.87)	(285.27)
	Employee Benefits Expense	701.32	694.39	627.06	2,637.96
	Finance Costs	19.52	7.88	30.90	80.18
	Depreciation and Amortization Expense	115.20	84.33	104.73	416.98
	Other Expenses	679.66	864.29	682.73	3,201.67
	Total Expenses	3,910.65	3,152.15	3,622.13	13,599.60
3	Profit before exceptional items and tax (1-2)	811.21	502.85	751.70	2,436.73
4	Exceptional Items	-	-	-	-
5	Profit before tax (3+4)	811.21	502.85	751.70	2,436.73
6	Tax expense:				
	(I) Current Tax	192.28	124.68	181.73	596.92
	(II) Deferred Tax	2.85	1.56	0.01	12.40
	(III) Earlier year taxes	-	-	-	0.30
	Total Tax (I+II+III)	195.13	126.24	181.74	609.62
7	Profit for the period (5-6)	616.08	376.61	569.96	1,827.11
8	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
A.	(ia) Re-measurement gain on defined benefit plans	2.44	(7.76)	5.84	9.76
	(ii) Income tax on the above item	(0.61)	1.95	(1.47)	(2.46)
B.	(i) Items that will be reclassified to profit or loss			-	-
	(ii) Income tax on the above item			-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.83	(5.81)	4.37	7.30
9	Total Comprehensive Income for the period (7+8)	617.91	370.80	574.33	1,834.41
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
11	Other Equity				13,686.99
12	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	7.46	4.56	6.90	22.11
	(2) Diluted	7.46	4.56	6.90	22.11

Notes:

- The above standalone unaudited financial results for the quarter ended on 30.06.2025 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2025. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter ended June 30, 2025, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June 2025 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGH
Managing Director
DIN-00027448



Place : Delhi
Dated : 13.08.2025

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2025

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,721.86	3,655.00	4,373.83	16,036.33
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	811.21	502.85	751.70	2,436.73
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	811.21	502.85	751.70	2,436.73
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	616.08	376.61	569.96	1,827.11
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	617.91	370.80	574.33	1,834.41
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	13,686.99
8	Earnings Per Share (of INR 10/- each)				
	(a) Basic	7.46	4.56	6.90	22.11
	(b) Diluted	7.46	4.56	6.90	22.11

NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended on 30.06.2025 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended on 30.06.2025 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above standalone unaudited financial results for the quarter ended on 30.06.2025 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2025. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015. The results for the quarter ended June 30, 2025, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2025 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGH
Managing Director
DIN-00027448

Place : Delhi
Dated : 13.08.2025



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2025

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2025 UNAUDITED	31.03.2025 AUDITED	30.06.2024 UNAUDITED	31.03.2025 AUDITED
1	INCOME				
	Revenue from operations	4,649.64	3,516.93	4,311.46	15,645.08
	Other Income	72.22	138.07	62.37	391.25
	Total Income	4,721.86	3,655.00	4,373.83	16,036.33
2	EXPENSES				
	Cost of Materials Consumed	1,855.28	1,730.44	2,234.58	7,548.08
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	539.67	(229.18)	(57.87)	(285.27)
	Employee Benefit Expense	701.32	694.39	627.06	2,637.96
	Finance Costs	19.52	7.88	30.90	80.18
	Depreciation and Amortization Expense	115.20	84.33	104.73	416.98
	Other Expenses	679.66	864.29	682.73	3,201.67
	Total Expenses	3,910.65	3,152.15	3,622.13	13,599.60
3	Profit before exceptional items and tax (1-2)	811.21	502.85	751.70	2,436.73
4	Exceptional Items				
5	Profit before tax (3+4)	811.21	502.85	751.70	2,436.73
6	Tax expense:				
	(I) Current Tax	192.28	124.68	181.73	596.92
	(III) Deferred Tax	2.85	1.56	0.01	12.40
	(II) Earlier year taxes				0.30
	Total Tax (I+II+III)	195.13	126.24	181.74	609.62
7	Profit for the period (5-6)	616.08	376.61	569.96	1,827.11
8	Share in Profit of Associate	70.20	28.07	70.00	326.05
9	Profit for the period (7+8)	686.28	404.68	639.96	2,153.16
10	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
A	(ia) Re-measurement gain on defined benefit plans	2.44	(7.76)	5.84	9.76
	(ii) Income tax on the above item	(0.61)	1.95	(1.47)	(2.46)
B	(i) Items that will be reclassified to profit or loss				
	(ii) Income tax on the above item				
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.83	(5.81)	4.37	7.30
11	Total Comprehensive Income for the period (7+8)	688.11	398.87	644.33	2,160.46
12	Net profit attributable to:				
	Owners of the holding company				
	Non-controlling interest				
13	Other comprehensive income attributable to:				
	Owners of the holding company				
	Non-controlling interest				
14	Total Comprehensive Income attributable to (10+11)				
	Owners of the holding company				
	Non-controlling interest				
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
16	Other Equity				14,513.95
17	Earnings per equity share (face value of Rs. 10/- each) not annualised				
	(1) Basic	8.30	4.90	7.74	26.06
	(2) Diluted	8.30	4.90	7.74	26.06

Notes:

- The above consolidated unaudited financial results for the quarter ended on 30.06.2025 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2025. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter ended June 30, 2025, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter ended on 30.06.2025 include the results of following:-
Associate Companies - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June, 2025 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 13.08.2025

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RHICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : btd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2025

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,721.86	3,655.00	4,373.83	16,036.33
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	811.21	502.85	751.70	2,436.73
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	811.21	502.85	751.70	2,436.73
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	686.28	404.68	639.96	2,153.16
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	688.11	398.87	644.33	2,160.46
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	14,513.95
8	Earnings Per Share (of INR 10/- each)				
	(a) Basic	8.30	4.90	7.74	26.06
	(b) Diluted	8.30	4.90	7.74	26.06

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter ended on 30.06.2025 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter ended on 30th June 2025 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter ended on 30.06.2025 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2025 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 13.08.2025

Annexure-I

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015") read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

S.No	Particulars	Debendra Kumar Sabat	Naresh Kumar Singla	Suresh Chand Singla
1.	Reason for change viz. appointment, Re-appointment; resignation; removal, death or otherwise	Appointment of Mr. Debendra Kumar Sabat (DIN-00802225) as Additional Independent Director	Re-appointment of Mr. Naresh Kumar Singla (DIN: 00027448) as Managing Director of the Company	Re-appointment of Mr. Suresh Chand Singla (DIN: 00027706) as Managing Director of the Company
2.	Date of appointment/re-appointment/cessation (as applicable) & terms of appointment / re-appointment	<p>Date of appointment- August 13, 2025</p> <p>Terms of appointment He shall be Appointed in the category of Non-Executive as Additional Independent Director, who shall hold office upto the date of forthcoming Annual General Meeting of the Company.</p> <p>Further regularisation of his appointment is proposed in the forthcoming Annual General Meeting for a period of 5 years.</p>	<p>Date of Re-appointment- 1st April, 2026</p> <p>Terms of re-appointment He shall be re appointed as Managing Director (Executive) of the Company for a further term of Five years beginning from 1st April, 2026 to 31st March, 2031, and who shall not liable to retire by rotation, subject to the members approval in the forthcoming Annual General Meeting.</p>	<p>Date of Re-appointment- 1st April, 2026</p> <p>Terms of re-appointment He shall be re appointed as Managing Director (Executive) of the Company for a further term of Five years beginning from 1st April, 2026 to 31st March, 2031, and who shall not liable to retire by rotation, subject to the members approval in the forthcoming Annual General Meeting.</p>
3.	Brief profile (in case appointment)	Mr. Debendra Kumar Sabat is a seasoned legal professional with over 20 years of advocacy experience, enrolled with the Supreme Court of India	He possesses expertise in Accounts, Finance, Project Development, and Implementation, with a strong focus on financial planning and execution of strategic initiatives.	He has expertise in Production and Quality Control of Microbiological Culture Media, Media Bases, and other

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com, accounts@titanbiotechltd.com, purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in

		<p>and the Delhi High Court. He served as Central Government Counsel at the Supreme Court (2019–2022) and has represented key institutions such as EPFO, PFRDA, University of Delhi, and the Armed Forces Tribunal. He has also worked as a Consultant (Law) with SFIO and served as Guest Faculty at the Delhi Police Training Center.</p> <p>Mr. Sabat regularly appears before NCLT, NCLAT, Consumer Forums, IP Tribunals, DRTs, and Arbitration forums, and is a designated Notary Public. Prior to his legal career, he gained experience in the field of finance, taxation, and corporate law.</p>		<p>biological products</p> <p>He is also well-versed in product marketing and brand building, contributing to both operational excellence and market growth.</p>
4.	disclosure of relationships between directors (in case of appointment of a director	Mr. Debendra Kumar Sabat is not related to any of the Director of the Company.	Mr. Naresh Kumar Singla is Father of Mr. Raja Singla & Mr. Shivom Singla	<ul style="list-style-type: none"> • Mr. Suresh Chand Singla is husband of Mrs. Manju Singla. • He is also father of Ms. Supriya Singla & Mr. Udit Singla
5.	Shareholding, if any in company	NIL	34,510 Equity Shares held in his own name	1,05,671 Equity Shares held in his own name
6.	Name of listed entities in which the	Not Applicable	Not Applicable	Not Applicable



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

	resigning Director holds directorship			
7.	Information as required under BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018	Mr. Debendra Kumar Sabat is not debarred from holding the office of director by virtue of any order of SEBI or any other authority.	Mr. Naresh Kumar Singla is not debarred from holding the office of director by virtue of any order of SEBI or any other authority.	Mr. Suresh Chand Singla is not debarred from holding the office of director by virtue of any order of SEBI or any other authority.

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

ANNEXURE-II

List of Directors w.e.f. 13-08-2025

S.No	Name of Directors	DIN	Designation
1.	MANJU SINGLA	00027790	Director
2.	NARESH SINGLA	00027448	Managing Director
3.	SUPRIYA SINGLA	03526583	Director
4.	SURESH CHAND SINGLA	00027706	Managing Director
5.	RAJA SINGLA	03523719	Whole-time director
6.	UDIT SINGLA	03526575	Whole-time director
7.	SHIVOM SINGLA	03615519	Whole-time director
8.	DHAIRYA MADAN	10284820	Independent Director
9.	BRIJESH KUMAR SINGH	10297977	Independent Director
10.	ROHIT JAIN	07191154	Independent Director
11.	ABHISHEK AGARWAL	07286832	Independent Director
12.	DEBENDRA KUMAR SABAT	00802225	Independent Director

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in